Overview

Neuroprotection in Acute Ischemic Stroke

Status:
Unknown status

Trial end date:
2020-11-02

Target enrollment:

Participant gender:

Summary

This is a pilot randomized control trial (RCT) to explore the possible beneficial effect of a novel combination therapy consisting of molecular hydrogen H2 plus minocycline ("H2M"), on neurological recovery after acute ischemic stroke.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Stony Brook University

Collaborator:

Korea Institute of Science and Technology

Treatments:

Minocycline